Department of Medical and Surgical Sciences for Children & Adults, University of Modena and Reggio Emilia, 41126 Modena, Italy.
Internal and Metabolic Medicine, AOU of Modena-Baggiovara, 41126 Modena, Italy.
Biomolecules. 2024 Sep 28;14(10):1227. doi: 10.3390/biom14101227.
Cholestasis is a clinical and laboratory syndrome indicating impaired bile production or excretion. One of the hallmark symptoms of cholestasis is pruritus. Itch can be severe and debilitating for patients, impacting their quality of life similarly to pain, and, in some cases, it can be refractory. Current therapies like anion exchange resins and rifampicin, offer partial relief but with side effects. Effective, well-tolerated treatments are urgently needed. This literature review examines existing options (bile acid sequestrants, antihistamines, opioid antagonists, sertraline, and rifampicin) and explores novel therapies (monoclonal antibodies, PPAR agonists, and bile-acid-based therapies). We analyze mechanisms, limitations, and adverse effects to aid clinicians and researchers. Novel approaches include monoclonal antibodies to inhibit bile recirculation and PPAR agonists targeting pruritus signaling. Despite the limited current options, ongoing research promises better treatments for cholestatic pruritus, addressing its distressing impact. In summary, cholestasis-associated pruritus poses a significant challenge with limited treatments. Advancements in understanding its pathophysiology offer hope for more effective therapies in the future.
胆汁淤积症是一种临床和实验室综合征,表明胆汁生成或排泄受损。胆汁淤积症的一个标志症状是瘙痒。瘙痒可能对患者造成严重的影响,使其身体虚弱,对生活质量的影响类似于疼痛,在某些情况下,瘙痒可能难以缓解。目前的治疗方法,如阴离子交换树脂和利福平,只能提供部分缓解,但存在副作用。因此,迫切需要有效的、耐受良好的治疗方法。本文综述了现有的治疗选择(胆汁酸螯合剂、抗组胺药、阿片受体拮抗剂、舍曲林和利福平),并探讨了新的治疗方法(单克隆抗体、过氧化物酶体增殖物激活受体激动剂和胆汁酸为基础的治疗)。我们分析了这些方法的机制、局限性和不良反应,以帮助临床医生和研究人员。新的方法包括单克隆抗体抑制胆汁再循环和针对瘙痒信号的过氧化物酶体增殖物激活受体激动剂。尽管目前的治疗选择有限,但正在进行的研究有望为胆汁淤积性瘙痒提供更好的治疗方法,以解决其带来的困扰。总之,胆汁淤积相关的瘙痒是一个具有挑战性的问题,目前的治疗方法有限。对其病理生理学的深入了解为未来更有效的治疗方法带来了希望。